Latest News About Orphines

Here’s the latest I can share based on recent public reporting.

• The term “orphines” has been used in two distinct contexts recently: a new class of synthetic opioids appearing in U.S. street drug supply, and unrelated corporate topics with similar names in pharma news. The most widely reported, up-to-date coverage concerns orphines as potent illegal opioids linked to overdose risks, with initial detections expanding from a handful of states and appearing in public-health alerts. Authorities warn these compounds can be significantly more dangerous than fentanyl and may evade standard screening.[5]

• Separately, there have been pharmaceutical company mentions of Orphagen and Orphazyme in older news roundups, but those items date from 2022–2025 and do not reflect current nationwide public-health developments about illegal orphines. If you’re looking for corporate updates specifically about a company named Orphagen or Orphazyme, I can pull the latest filings and press releases.[1][4][8]

If you want, I can perform a focused search for:

• State-by-state overdose trends and federal alerts about orphines (latest public-health data).
• Current regulatory or law-enforcement advisories on these substances.
• Recent press releases and earnings/upgrades for Orphagen and Orphazyme (to distinguish corporate news from the opioid topic).

Would you like me to narrow to a region (e.g., Brazil, given your São Paulo location) or pull the latest official health and regulatory updates first?

Citations:

• New class of orphines and rising presence in the U.S. states, with alerts and regional spread discussed in recent reporting.[5]
• Historical corporate news items about Orphagen and Orphazyme, which predate current opioid-focused coverage.[4][8][1]